Director and 10% Owner Makes Substantial $5M Stock Purchase Post-Offering
Summary
A Director and 10% Owner of ALX Oncology Holdings made a nearly $5 million open market purchase of company stock, signaling strong confidence shortly after a significant public offering.
Key Events
-
Substantial Insider Purchase
Corey S. Goodman, a Director and 10% Owner, acquired $4,999,999 worth of common stock in an open market transaction on February 2, 2026.
-
Post-Offering Confidence Signal
This significant purchase occurred just days after the company finalized a $150 million public offering on January 30, 2026, indicating strong insider conviction despite recent dilution.
-
Significant Stake Increase
The transaction represents a substantial investment relative to the company's market capitalization, increasing the reporting owner's indirect holdings to 8,453,038 shares.
Analysis
Corey S. Goodman, a Director and 10% Owner, made a significant open market purchase of nearly $5 million in ALX Oncology Holdings stock. This substantial investment, representing a notable portion of the company's market capitalization, occurred just days after the company finalized a $150 million public offering on January 30, 2026. The timing of this large insider buy, especially following a dilutive capital raise, signals strong confidence in the company's future prospects and the value of its shares. The stock is also trading near its 52-week high, further underscoring the conviction behind this purchase.
At the time of this filing, ALXO was trading at $2.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $109M. The 52-week trading range was $0.40 to $2.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.